HAMP
protein-codinghepcidin antimicrobial peptide
Gene summary
The product encoded by this gene is involved in the maintenance of iron homeostasis, and it is necessary for the regulation of iron storage in macrophages, and for intestinal iron absorption. The preproprotein is post-translationally cleaved into mature peptides of 20, 22 and 25 amino acids, and these active peptides are rich in cysteines, which form intramolecular bonds that stabilize their beta-sheet structures. These peptides exhibit antimicrobial activity against bacteria and fungi. Mutations in this gene cause hemochromatosis type 2B, also known as juvenile hemochromatosis, a disease caused by severe iron overload that results in cardiomyopathy, cirrhosis, and endocrine failure. [provided by RefSeq, Oct 2014]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~4.4 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0019257
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0013220
Submitter: ClinGen
The HAMP gene encodes hepcidin, a human antimicrobial peptide that is predominantly expressed in the liver. Hepcidin functions as a key iron-regulatory hormone, playing a central role in systemic iron homeostasis (PMIDs: 11034317, 11113131, 11113132). In 2003, HAMP was first implicated in autosomal recessive hemochromatosis type 2B (HH2B) (Roetto et al., PMID: 12469120). HH2B is characterized by elevated transferrin saturation, serum ferritin and iron levels, increased liver transaminases, and hepatic iron accumulation. Clinical manifestations include cirrhosis, liver fibrosis, hepatosplenomegaly, cardiomyopathy, hyperpigmentation, hypogonadism, diabetes, arthritis, and hematological abnormalities. A range of pathogenic variants in HAMP has been reported in affected individuals, including missense, nonsense, and frameshift mutations, as well as a recurrent 5′UTR base change. This curation includes 12 unrelated probands and 9 unique variants (PMIDs: 12469120, 14630809, 15024747, 15099344, 15198949, 16960153, 19342478, 22297252, 29085829, 33016646, 36925058). The gene-disease relationship is strongly supported by case-level evidence, exceeding the maximum score of 12 points. Additional support comes from animal models, expression, and functional studies (PMIDs: 11034317, 11113131, 11113132, 16574947, 24816174, 15933050, 27897970, 12704388). Northern blot and RT-PCR analyses of human tissues confirmed that hepcidin is predominantly expressed in the liver (PMIDs: 11034317, 11113132). Studies in mice demonstrated that hepcidin expression is upregulated in response to increased serum and hepatic iron levels. Hepcidin regulates systemic iron concentration via the hepcidin–ferroportin axis, underscoring its central role in iron homeostasis (PMIDs: 11113132, 15933050). HAMP knockout (KO) mouse models recapitulate key features of the human HH2B phenotype, including elevated hepatic iron, serum iron, and ferritin levels (PMIDs: 16574947, 24816174). KO mice fed an iron-rich diet developed elevated liver enzymes, hepatomegaly, chronic liver inflammation, liver cell apoptosis, and tissue fibrosis, suggesting that hepcidin deficiency combined with iron overload contributes to liver injury (PMID: 24816174). Furthermore, transgenic overexpression of hepcidin in HFE KO mice rescued hepatic iron accumulation, reinforcing hepcidin’s role in iron regulation (PMID: 12704388). Cardiac-specific deletion of hepcidin led to heart enlargement, increased expression of hypertrophic markers MYH7 and NPPB, and cardiomyocyte apoptosis. These KO mice exhibited reduced cardiac function and impaired activity of iron-dependent and mitochondrial enzymes, which were restored upon iron supplementation. Additionally, ferroportin expression was upregulated in KO heart tissue, consistent with the loss of hepcidin-mediated regulation. This local iron deficiency, driven by enhanced iron efflux, was reversed by treating cultured cardiomyocytes with hepcidin (PMID: 27897970). In summary, there is definitive evidence supporting the association between HAMP and autosomal recessive hemochromatosis type 2B. This relationship has been consistently demonstrated in both research and clinical diagnostic settings and has remained robust over time. This classification was approved by the ClinGen IEM GCEP at the meeting on October 10, 2025 (SOP Version 11).
Inheritance Pattern: AR
Disease ID:MONDO:0013220
Submitter: Genomics England PanelApp
Inheritance Pattern: AR
Disease ID:MONDO:0013220
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0013220
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0013220
Submitter: G2P
Clinical Genomic Database (CGD)
Manifestation: Biochemical; Cardiovascular; Endocrine; Gastrointestinal; Hematologic
Intervention: Biochemical; Gastrointestinal; Hematologic
Rationale: Patients may benefit from surveillance related to iron overload, and from interventions such as venesection; Certain agents should be avoided (eg, alcohol consumption; iron-containing compounds; uncooked seafood); Hormone therapy may be beneficial in order to prevent osteoporosis
Comments: Digenic inheritance (with HFE) has been reported; HAMP variants may contribute to severity/manifestations of hemochromatosis associated with variants in other genes
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to HAMP variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_021175.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 31 | 32 | |||
| missense | 1 | 1 | 16 | 2 | 20 | |
| nonsense | 1 | 1 | 2 | 4 | ||
| start loss | 1 | 1 | ||||
| frameshift | 2 | 2 | 4 | |||
| splice donor/acceptor (+/-2bp) | 1 | 1 | ||||
| Total | 4 | 4 | 21 | 33 | 0 | 62 |
Highest pathogenic variant AF is 0.000018591001
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_066998.1 | 3 | MANE Select | |
| Ensembl | ENSP00000222304.2 | 3 | MANE Select | |
| Ensembl | ENSP00000471894.1 | 3 | Standard | |
| Ensembl | ENSP00000539807.1 | 2 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| hamp | Danio rerio | Structure: vertebra Quality: decreased occurrence abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Iron metabolism in placenta
- Hfe effect on hepcidin production
Biological Process
- negative regulation of transcription by RNA polymerase II
- cellular iron ion homeostasis
- acute-phase response
- immune response
- aging
Molecular Function
- hormone activity
Cellular Component
- extracellular region
- extracellular space
- intercalated disc
- apical cortex
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000598398
- Coding exons
- 3
- Length
- 4428
- Individuals with no LoFs
- 125738
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 10
- Defined
- 125748
- p
- 0.0000398
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.151 | 43 | 45.9 | 0.937 | 0.00000259 | 542 |
| Missense (PolyPhen) | 7 | 13.171 | 0.53146 | 147 | ||
| Synonymous | -1.90 | 29 | 18.6 | 1.56 | 0.00000114 | 162 |
| Loss of Function | 0.198 | 3 | 3.39 | 0.884 | 1.50e-7 | 32 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000062 | 0.000062 | rare |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00038 | 0.00038 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000018 | 0.000018 | rare |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Liver-produced hormone that constitutes the main circulating regulator of iron absorption and distribution across tissues. Acts by promoting endocytosis and degradation of ferroportin, leading to the retention of iron in iron-exporting cells and decreased flow of iron into plasma. Controls the major flows of iron into plasma: absorption of dietary iron in the intestine, recycling of iron by macrophages, which phagocytose old erythrocytes and other cells, and mobilization of stored iron from hepatocytes (PubMed:22306005). {ECO:0000269|PubMed:22306005}.;
- Disease
- DISEASE: Hemochromatosis 2B (HFE2B) [MIM:613313]: A juvenile form of hemochromatosis, a disorder of iron metabolism with excess deposition of iron in a variety of organs leading to their failure, bronze skin pigmentation, hepatic cirrhosis, arthropathy and diabetes. The most common symptoms of juvenile hemochromatosis at presentation are hypogonadism and cardiomyopathy. {ECO:0000269|PubMed:12915468, ECO:0000269|PubMed:14630809, ECO:0000269|PubMed:14633868, ECO:0000269|PubMed:14670915, ECO:0000269|PubMed:15099344}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.542
Intolerance Scores
- LoFtool
- 0.438
- RVIS EVS
- 0.46
- RVIS percentile EVS
- 78.16
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.114
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |